All eyes on Revolution, bispecific antibodies and more at ASCO26

All eyes at ASCO 2026 are on Revolution Medicine’s daraxonrasib in pancreatic cancer and on several new bispecific‑antibody datasets across solid tumors and hematology.

Bispecific antibodies highlight:
Summit Therapeutics and Akeso’s PD‑1 × VEGF bispecific ivonescimab (Harmoni‑6) in first‑line NSCLC, Bristol‑Myers Squibb’s EGFRxHER3 bispecific ADC izalontamab brengitecan (triple‑negative breast cancer), and AbbVie’s PSMA/STEAP1 bispecific ADC ABBV‑969 in mCRPC.

Experts anticipate that data presented this year will move bispecifics into earlier‑line and higher‑risk settings in lymphoma and myeloma, and will broaden the role of bispecifics and ADCs in solid‑tumor care.